3rd ADC & Combinations Day
Wednesday October, 9

9.00 Chair’s Opening Remarks

Jay Harper, Associate Director, AstraZeneca

Improving Understanding of Various Combination Approaches & the Combination Landscape

9.10 A Review of the Combination Landscape

• Update on the key movements in the clinic
• Insight into the rapidly evolving pipeline
• Analysis of novel clinical ADCs

Letrishka Anthony, Senior Analyst, Beacon Targeted Therapies, Hanson Wade

9.40 Combining ADCs with…… Evolution of ADC Combinatorial Therapies

• Overview of ADC combination strategies evaluated in the clinic
• Highlights and difficulties with ADC combinations
• Beyond chemo and IO: next wave of ADC combinations

Jay Harper, Associate Director, AstraZeneca

10.10 Speed Networking

11.00 Morning Break

Exploring Rational Approaches to Combination Trials

11.30 The Impact of Antibody-Drug Conjugate Distribution on Multiple Mechanisms of Action & Combination Therapy

• Antibody-drug conjugates can work through multiple mechanisms of action (MoA): payload killing, cell signalling blockade, and Fc-effector functions
• The relative contribution of each MoA can be used to increase overall efficacy at tolerable doses, thereby increasing the therapeutic window
• These MoA can be used to improve the efficacy of immuno-oncology agents such as checkpoint inhibitors

Greg Thurber, Associate Professor, University of Michigan

12.00 Sharing Clinical Challenges & Considerations for a Combination Trial

• Why should an ADC be combined with an additional drug?
• When should two investigational agents be combined?
• How do you determine relationship of combination agents with adverse events?

Scott Tagawa, Associate Professor in Hematology, Oncology, Clinica l Medicine & Urology, Weill Cornell - Cornell University

12.30 Lunch

Counting on Combos: Evaluating Future Development of Combinations

1.30 Rapid Advancements of Oncology Landscape: Where Do ADC Sit in an Immuno-Oncology World?

• The current landscape of IO
• The clinical landscape of IO plus ADC
• How philanthropic investment models could help advance IO combo trials

Jun Tang, Cancer Research Institute

2.00 Combination Therapy with Telisotuzumab Vedotin, an MMAE ADC Target c-Met, in NSCLC

• Telisotuzumab vedotin is active agent as a monotherapy in NSCLC
• Telisotuzumab vedotin has acceptable safety profile in NSCLC
• Explore how Telisotuzumab Vedotin can be combined with approved drugs used in treatment of NSCLC

Louie Naumovski, Senior Director – Medical, AbbVie

2.30 Afternoon Break

Novel Development for ADCs in Combination

3.30 Discovery of an ADC Platform Employing an Immunostimulatory Payload

• Overview of the considerations and benefits of combining I/O payloads with anADC approach
• Application of Mersana’s modular Synthemer platform technology to create IOADCs
• Review in vitro and in vivo characterization of selected examples in relevant model systems

Jeremy Duvall, Associate Director, Mersana

4.00 Panel Discussion: Reviewing the Rationale for Combination Studies & Target Selection

• Discuss the approaches of ADC combinations that have been tested in clinic and where available, monotherapy efficacy and safety data for the ADC, the combination partner and the combination
• Review of the various types of combinations and where we see greatest potential
• Summary of the combination day and where to go from here

4.30 Chair’s Closing Remarks
Jay Harper, Associate Director, AstraZeneca